Thomas W. Elward has been the CEO of Dyne Therapeutics, Inc. since 2011. He has a strong background in the energy industry, having previously served as President and COO of CMS Enterprises, where he gained extensive management experience. Elward also...

Thomas W. Elward has been the CEO of Dyne Therapeutics, Inc. since 2011. He has a strong background in the energy industry, having previously served as President and COO of CMS Enterprises, where he gained extensive management experience. Elward also has technical expertise with a master's degree in nuclear engineering. He has played a significant role in various power-related projects and has received awards for excellence in safety and environmental stewardship. Interestingly, he takes a hands-on approach to leadership and is actively involved in major decisions, including the CEO search for Dyne. In 2023, his compensation totalled approximately $756,786, but what stands out is his historical compensation peaked at over $8.3 million in 2016. Elward's stock holdings have seen significant fluctuations, showing he has a vested interest in Dyne's performance, which aligns with his leadership style. Despite ups and downs in the stock value throughout his career, Elward continues to focus on scaling the company, which is essential for its growth and survival in a competitive market.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Dyne Therapeutics, Inc. CEOs

D

Thomas W. Elward

CEO of Dyne Therapeutics, Inc.

Sector of Economy

Healthcare

Born

July 30, 2024 - 0 years ago

CEO of Dyne Therapeutics, Inc. for

13 years 5 months (Dec 2011 - Present)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Thomas W. Elward

Holdings

See how much did Thomas W. Elward make over time.

As the CEO of Dyne Therapeutics, Thomas W. Elward has fluctuated holdings that reflect his deep connection to the company's performance. Over the years, his stock holdings have spiked and dipped significantly. For example, at the peak of his career...

As the CEO of Dyne Therapeutics, Thomas W. Elward has fluctuated holdings that reflect his deep connection to the company's performance. Over the years, his stock holdings have spiked and dipped significantly. For example, at the peak of his career in 2016, his compensation, coupled with vested stocks, hit around $8.3 million. However, in recent years, the total compensation dropped to around $756,786 in 2023, indicating a careful alignment with corporate goals and performance. The stock price itself has seen a varied history; it was $899.75 in September 2020 but dropped to lows around $228.51 in June 2022. Currently, it's valued around $492.53. This shift shows the volatility of the stock market and its impact on executive holdings, but Elward’s significant ownership indicates his commitment to navigating these ups and downs for company success. Through significant variances, his connection to the company's health remains paramount, illustrating the blend of risk and reward that comes with leadership in this sector.

Mar 11, 2025

D

shares

DYN @ $11.87

Insider Trading

See recent insider trades of Thomas W. Elward.

DYN

$28.58K

DYN at $5.72/share

Mar 31, 2011

Purchase

Compensation History

See how much did Thomas W. Elward make over time.

Elward's compensation as CEO has varied widely over his tenure at Dyne Therapeutics. In 2022, he was compensated around $4.2 million, showcasing a significant performance-based bonus reflecting his impactful leadership. However, in 2023, the total fell to approximately $756,786 due to shifting performance metrics and decisions by the board regarding executive pay that align with company success. His base salary in 2023 was $497,888, and he received an individual bonus of $258,902, which was tied to achieving specific targets. Notably, he received no vested stock or options that year, indicating a move toward variable compensation based strictly on annual performance achievements. Overall, his compensation setup illustrates a strategic focus on linking pay to the company’s broader performance goals.

Year

2023

Total Compensation

$757.79K

Salary

$497.89K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on motivating executives to achieve short- and long-term results.

Bonus

$258.90K

Board Justification

The bonus is based on individual and corporate performance metrics established by the board of directors for the year 2023.

Other

$996.00

Board Justification

Other compensation includes long-term disability insurance premiums and group term life insurance premiums in excess of statutory limits.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

Performance metrics include individual and corporate performance goals set by the board of directors.

Other Dyne Therapeutics, Inc. CEOs

Here are other CEOs of Dyne Therapeutics, Inc.

Bruce A. Williamson

CEO of Dyne Therapeutics, Inc.

December 2007 - Invalid Date

Robert C. Flexon

CEO of Dyne Therapeutics, Inc.

January 2012 - Present